Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions
Moderate COVID-19-infection
Interventions
DRUG

human SARS-CoV 2 specific T lymphocytes

"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."

Trial Locations (1)

50937

Department I for Internal Medicine University Hospital of Cologne, Cologne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ZKS Köln

OTHER

collaborator

Hannover Medical School

OTHER

collaborator

Miltenyi Biomedicine GmbH

INDUSTRY

lead

Universitätsklinikum Köln

OTHER